3/15
11:31 am
bbio
A Look At BridgeBio Pharma (BBIO) Valuation After Strong Long Term Returns And Recent Share Pullback [Yahoo! Finance]
Low
Report
A Look At BridgeBio Pharma (BBIO) Valuation After Strong Long Term Returns And Recent Share Pullback [Yahoo! Finance]
3/12
10:01 pm
bbio
BridgeBio Pharma Touts Attruby Uptake, Bayer's Europe Rollout and 2026-28 Pipeline Timelines at Leerink Conf [Yahoo! Finance]
Low
Report
BridgeBio Pharma Touts Attruby Uptake, Bayer's Europe Rollout and 2026-28 Pipeline Timelines at Leerink Conf [Yahoo! Finance]
3/12
11:07 am
bbio
BridgeBio Pharma (BBIO) had its "outperform" rating reaffirmed by Leerink Partners.
Low
Report
BridgeBio Pharma (BBIO) had its "outperform" rating reaffirmed by Leerink Partners.
3/11
02:25 pm
bbio
BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9 [Yahoo! Finance]
Low
Report
BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9 [Yahoo! Finance]
3/11
02:00 pm
bbio
BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9
Low
Report
BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9
3/10
10:01 pm
bbio
BridgeBio (BBIO) Soars 13% on Double-Digit Price Target Upgrade [Yahoo! Finance]
Medium
Report
BridgeBio (BBIO) Soars 13% on Double-Digit Price Target Upgrade [Yahoo! Finance]
3/10
05:04 pm
bbio
BridgeBio Pharma (BBIO) had its "overweight" rating reaffirmed by Barclays PLC.
Medium
Report
BridgeBio Pharma (BBIO) had its "overweight" rating reaffirmed by Barclays PLC.
3/10
03:37 pm
bbio
BridgeBio Pharma (BBIO) had its price target raised by JPMorgan Chase & Co. from $89.00 to $94.00. They now have an "overweight" rating on the stock.
Low
Report
BridgeBio Pharma (BBIO) had its price target raised by JPMorgan Chase & Co. from $89.00 to $94.00. They now have an "overweight" rating on the stock.
3/10
09:00 am
bbio
BridgeBio Pharma (BBIO) is now covered by William Blair. They set an "outperform" rating on the stock.
High
Report
BridgeBio Pharma (BBIO) is now covered by William Blair. They set an "outperform" rating on the stock.
3/7
04:39 pm
bbio
Does Positive Phase 3 BBP-418 Data in LGMD2I/R9 Change The Bull Case For BridgeBio Pharma (BBIO)? [Yahoo! Finance]
Low
Report
Does Positive Phase 3 BBP-418 Data in LGMD2I/R9 Change The Bull Case For BridgeBio Pharma (BBIO)? [Yahoo! Finance]
3/7
02:33 am
bbio
How The BridgeBio Pharma (BBIO) Narrative Is Shifting With Attruby And Late Stage Pipeline [Yahoo! Finance]
Low
Report
How The BridgeBio Pharma (BBIO) Narrative Is Shifting With Attruby And Late Stage Pipeline [Yahoo! Finance]
3/6
10:36 am
bbio
Truist Raises Its Price Target on BridgeBio Pharma, Inc. (BBIO) to $95 and Maintains a Buy Rating [Yahoo! Finance]
Low
Report
Truist Raises Its Price Target on BridgeBio Pharma, Inc. (BBIO) to $95 and Maintains a Buy Rating [Yahoo! Finance]
3/4
07:30 am
bbio
BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference
Medium
Report
BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference
3/3
02:33 am
bbio
BridgeBio Pharma (BBIO) Achieves Record 2025 Revenue Driven by Attruby Commercial Success [Yahoo! Finance]
Low
Report
BridgeBio Pharma (BBIO) Achieves Record 2025 Revenue Driven by Attruby Commercial Success [Yahoo! Finance]
2/25
12:58 pm
bbio
BridgeBio Pharma (BBIO) had its price target lowered by Oppenheimer Holdings, Inc. from $83.00 to $81.00. They now have an "outperform" rating on the stock.
Low
Report
BridgeBio Pharma (BBIO) had its price target lowered by Oppenheimer Holdings, Inc. from $83.00 to $81.00. They now have an "outperform" rating on the stock.
2/25
12:58 pm
bbio
BridgeBio Pharma (BBIO) had its price target raised by Truist Financial Corporation from $86.00 to $95.00. They now have a "buy" rating on the stock.
Low
Report
BridgeBio Pharma (BBIO) had its price target raised by Truist Financial Corporation from $86.00 to $95.00. They now have a "buy" rating on the stock.
2/25
10:46 am
bbio
BridgeBio Pharma (BBIO) had its price target raised by Morgan Stanley from $96.00 to $98.00. They now have an "overweight" rating on the stock.
Low
Report
BridgeBio Pharma (BBIO) had its price target raised by Morgan Stanley from $96.00 to $98.00. They now have an "overweight" rating on the stock.
2/25
12:27 am
bbio
BridgeBio Pharma Inc (BBIO) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
Medium
Report
BridgeBio Pharma Inc (BBIO) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
2/24
06:47 pm
bbio
BridgeBio Pharma Q4 Earnings Call Highlights [Yahoo! Finance]
Medium
Report
BridgeBio Pharma Q4 Earnings Call Highlights [Yahoo! Finance]
2/24
04:32 pm
bbio
BridgeBio Pharma: Q4 Earnings Snapshot [Yahoo! Finance]
Medium
Report
BridgeBio Pharma: Q4 Earnings Snapshot [Yahoo! Finance]
2/24
04:01 pm
bbio
BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates
Medium
Report
BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates
2/23
07:30 am
bbio
BridgeBio to Participate in March Investor Conferences
Low
Report
BridgeBio to Participate in March Investor Conferences
2/17
06:22 pm
bbio
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2/17
08:03 am
bbio
BridgeBio Pharma (NASDAQ:BBIO) had its price target raised by analysts at HC Wainwright from $90.00 to $100.00. They now have a "buy" rating on the stock.
Low
Report
BridgeBio Pharma (NASDAQ:BBIO) had its price target raised by analysts at HC Wainwright from $90.00 to $100.00. They now have a "buy" rating on the stock.
2/17
07:30 am
bbio
BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET
Low
Report
BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET